Gary Schiller, MD
Enriched profileProfessor of Medicine (Professor-in-Residence); Director, Hematological Malignancies Stem Cell Transplant Program; Chair, FEC Governance Sub-Committee · University of California Los Angeles David Geffen School of Medicine
Gary Schiller is Professor of Medicine (Professor-in-Residence); Director, Hematological Malignancies Stem Cell Transplant Program; Chair, FEC Governance Sub-Committee at University of California Los Angeles David Geffen School of Medicine. OpenAlex indexes 735 publications with 23,227 citations (h-index 72); ClinicalTrials.gov lists 19 registered studies with this person as an investigator. By OpenAlex citation count, this profile ranks in the top 10% of Hematology / Oncology profiles in the findmyKOL directory.
Data verified 25 Aug 2026
Overview
Updated 14 Oct 2026
Gary Schiller, MD, is Professor of Medicine (Professor-in-Residence) at University of California Los Angeles David Geffen School of Medicine, Department of Medicine, Division of Hematology-Oncology. The public record shows 735 publications with 23,227 citations (h-index 72), centered on Acute Myeloid Leukemia Research, Multiple Myeloma Research and Treatments, Chronic Myeloid Leukemia Treatments. It also documents an investigator role on 19 registered clinical trials, industry payments reported by 36 companies.
- Most recent indexed publication: 2026 · Blood advances
- Top research focus: Acute Myeloid Leukemia Research
- 19 registered trials on ClinicalTrials.gov
- Open Payments reporting from 36 companies
Generated from the cited public record · current as of 14 Oct 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID; 13 in PubMed.
Total citations across indexed works.
Hirsch index (OpenAlex). i10-index 264.
Clinical & industry
trials, payments and federal fundingFederally funded research awards.
Contact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 14 Oct 2026
Listed as an investigator on 19 registered studies on ClinicalTrials.gov. The most recent:
- Evaluate the Safety, Tolerability, Pharmacokinetic Profile, Efficacy of Bl-M11D1
Sponsor: SystImmune Inc.
- An Extension Study for Patients Previously Enrolled in Studies With Pelabresib
Sponsor: Novartis Pharmaceuticals
- A Clinical Trial of BP1002 in Patients With Refractory/Relapsed Acute Myeloid Leukemia (AML)
Sponsor: Bio-Path Holdings, Inc.
Industry payments
Updated 14 Oct 2026
36 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:
- Karyopharm Therapeutics Inc.Program year20255 payments
- Geron CorporationProgram year20253 payments
- Autolus IncProgram year20253 payments
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
52.9%Kinase inhibitor52.9%Imatinib Mesylate100%Part D<11 patientsDermatology
47.1%Herpesvirus Nucleoside Analog DNA Polymerase Inhibitor47.1%Acyclovir100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
We didn't find any NIH-funded research awards for this person in NIH RePORTER. Why? →
Congress activity
Updated 14 Oct 2026
193 congress contributions (2004–2025) across AACR, ASCO, ASH, ESMO per OpenAlex. The most recent:
Published abstracts are attributed via the same ORCID-disambiguated authorship as publications, so each is DOI-verified. Podium roles (invited talks, session chairs) and oral/poster type are added as program data is confirmed.
Publications
Updated 14 Oct 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- Clinical outcomes of lentiviral vector gene therapy for sickle cell disease.
Blood advances
Clinical Trial2026 - Risk Prognostication After Hypomethylating Agents Combined With Venetoclax in AML: The PRISM Risk Model.
Journal of clinical oncology
Article2026 - Pivekimab Sunirine in Blastic Plasmacytoid Dendritic Cell Neoplasm.
Journal of clinical oncology
Clinical Trial2026 - RGI-2001 for the prophylaxis of acute graft-versus-host disease after allogeneic HCT.
Blood
Clinical Trial2025
Most-cited works
by citation count (OpenAlex)Network
Updated 14 Oct 2026
The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.
Online presence
Updated 14 Oct 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Owned accounts
public accounts run by this person- Doximity
doximity.com/pub/gary-schiller-md
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com ↗ - ResearchGate
researchgate.net/profile/Gary-Schiller
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →researchgate.net ↗
Mentions by others
where others cite or feature them- Facebook
facebook.com/OncLive/videos/dr-schiller-and-dr-fazal-on-standard-of-care-treatments-for-bpdcn/308332134209864
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →facebook.com ↗ - Other
onclive.com/authors/gary-j-schiller-md
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →onclive.com ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Background & recognition
Updated 14 Oct 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →uclahealth.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →uclahealth.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →uclahealth.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →uclahealth.org ↗
- BS
Biological Sciences, University of Southern California
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →uclahealth.org ↗ - Board Certified
Hematology, American Board of Internal Medicine
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →onclive.com ↗ - verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →uclahealth.org ↗
Editorial & leadership roles
journal and society appointments- Director
Hematological Malignancies Stem Cell Transplant Program, UCLA
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →medschool.ucla.edu ↗ - Chair
FEC (Faculty Executive Committee) Governance Sub-Committee, UCLA David Geffen School of Medicine
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →medschool.ucla.edu ↗ - Principal Investigator
multiple hematologic malignancy clinical trials (e.g., ZUMA-3, Beat AML Master Trial)
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →profiles.ucla.edu ↗
Awards & honors
honors on the public record- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →uclahealth.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →uclahealth.org ↗
Secondary affiliations
appointments beyond the home institution- UCLA Health Jonsson Comprehensive Cancer Center
Bowyer Oncology Center
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →uclahealth.org ↗ - Ronald Reagan UCLA Medical Center
Hematological Malignancies / Stem Cell Transplantation Unit
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →onclive.com ↗
Media & interviews
press, podcasts and appearances- Recurring video/written expert contributor
OncLive (author page; topics include AML heterogeneity, JAK inhibitors in myelofibrosis, CAR T-cell therapy, ZUMA-3 trial)
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →onclive.com ↗ - Recurring contributor
Targeted Oncology (author page)
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →targetedonc.com ↗ - Video interviews
VJHemOnc (topics include selinexor-based regimens in multiple myeloma, lintuzumab-Ac225 plus venetoclax in R/R AML, MRD conversion in AML)
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →vjhemonc.com ↗ - provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →oncologytube.com ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
Hagop Kantarjian, MD
The University of Texas MD Anderson Cancer Center
Jorge Cortes, MD
University of Alabama at Birmingham (UAB)
Ayalew Tefferi, MD
Mayo Clinic
Charles Sawyers, MD
Memorial Sloan Kettering Cancer Center